STAT+: Medicare paid substantially more for J&J’s Stelara when it was covered under Part D than under Part B
STAT
AUGUST 8, 2024
A popular biologic medicine used to combat autoimmune diseases cost Medicare and its beneficiaries considerably more when the injectable treatment was obtained at pharmacies rather than injected in physician offices due to different methods for determining payment, a new analysis found.
Let's personalize your content